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ABSTRACT
Introduction: Tobacco use is the leading cause of
preventable death in the UK. However, research
spending on tobacco-related disease, and particularly
smoking prevention, is thought to be low. We therefore
aimed to assess the relation between tobacco-related
research investment and disease burden from 2008 to
2012.
Methods: We used the Health Research Classification
System to classify UK government and charitable
research funding by broad health category and then by
tobacco prevention research and 18 WHO defined
tobacco-related diseases. We used UK mortality figures
to calculate disease-specific tobacco attributable deaths
and then compared disease specific and tobacco
prevention research investment with all cause and
tobacco attributable mortality over the 5-year period
and as annual averages.
Results: 12 922 research grants were identified with a
total value of £6.69bn, an annual average of £1.34bn.
Annually an average of 110 000 people die from
tobacco-related disease, approximately 20% of total
deaths. £130m is invested in researching tobacco-
related disease each year and £5m on tobacco
prevention, 10.8% and 0.42% of total annual research
funding, respectively. Prevention research equated to
an annual average of £46 per tobacco attributable
death or one pound for every £29 spent on tobacco-
related disease. Funding varied widely for diseases with
different numbers of deaths (eg, lung cancer £68 per
all cause death, cervical cancer £2500), similar
numbers of deaths (leukaemia £983 per death,
stomach cancer £43) or similar numbers of tobacco
attributable deaths (eg, colorectal cancer £5k,
pancreatic cancer £670, bladder cancer £340).
Conclusions: Tobacco-related research funding is not
related to burden of disease or level of risk. As a result
certain diseases receive a disproportionately low level
of research funding and disease prevention funding is
even lower.
INTRODUCTION
Tobacco use is the leading cause of prevent-
able death in the UK, killing ∼100 000
people every year.1 Half of all smokers die
prematurely as a consequence of their
smoking unless they quit,2 and their death is
often preceded by several years of ill health.3
Smoking is most prevalent among the most
disadvantaged in society,4 5 and is the largest
avoidable cause of social inequalities in
health and life expectancy.6 7 Wider society is
impoverished by the healthcare and wider
societal costs of smoking8–11 and smoking
contributes signiﬁcantly to levels of poverty
in the UK.12 Since smoking is entirely avoid-
able, preventing smoking is the most effect-
ive way to improve health and well-being in
the UK. Supporting research to improve
smoking cessation and prevent uptake of
smoking should therefore be a high priority
for research funders.
The UK government has recommended
that health research priorities should be
based on the country’s health needs and pri-
orities, which are set in relation to the
impact of disease and illness.13 However
researchers across a range of disciplines have
claimed that their speciﬁc research area is
underfunded14–16 and have used a variety of
disease impact or burden measures to
Strengths and limitations of this study
▪ Analysis of research funding was comprehensive
and over a 5-year period allowing for differences
in annual funding trends. However, it is likely
that some funding sources were missed; com-
mercial and industry funding was not included
since, to the best of our knowledge, it does not
influence national research policy.
▪ The study used internationally recognised
methods of categorising research funding and
calculating numbers of tobacco attributable
death; use of the smoking impact ratio may have
over-estimated the number of tobacco attribut-
able deaths.
▪ Using mortality as a measure of disease burden
is simple and unequivocal but excludes impact
of time spent ill or age of death.
▪ Methods used were simple and easily replicable
across research disciplines.
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support these claims.14 17–19 The huge detrimental con-
tribution of tobacco to the UK’s health and economy
would suggest that tobacco smoking is a priority for
research investment, but evidence to date on whether
this is actually the case in practice is lacking. This study
therefore aimed to assess the relation between invest-
ment in UK health research and disease burden, with a
particular focus on tobacco research and burden of
tobacco-related disease.
METHODS
Disease burden is usually estimated using one or a com-
bination of three measures: mortality, morbidity and the
impact of disease on the economy. For this study we
used mortality from 18 tobacco attributable diseases as
identiﬁed by the WHO.20 We obtained numbers of total
and disease speciﬁc deaths for the period 2008–2012,
broken down by age and sex, from the Ofﬁce of
National Statistics for England and Wales (ONS), the
General Register Ofﬁce for Scotland, and the Northern
Ireland Statistics and Research Agency.21–23 Diseases
were deﬁned using the International Classiﬁcation of
Diseases and Related Health Problems 10th Revision
(ICD-10).24 Deaths on breast and prostate cancer were
collected for comparison purposes from the same
sources.
Estimates of smoking prevalence by age and gender
were calculated for each year for the same period using
the smoking impact ratio (SIR), whereby deaths from
lung cancer are used as a proxy measure for smoking
prevalence.25 Estimates of age and sex-speciﬁc
tobacco-related relative risks (RR) were taken from
updated Cancer Prevention Study (CPS-II) ﬁgures.26
Disease, age and sex-speciﬁc population attributable
fractions were then calculated using the RR, the SIR and
the total number of deaths for each disease. These were
combined to establish disease speciﬁc total deaths attrib-
utable to tobacco and an overall total number of deaths
attributable to tobacco each year.
Research funding
Of the £3 billion of public funds provided annually for
medical research in the UK, one-third comes from the
National Institute for Health Research (NIHR),
one-third from the Medical Research Council (MRC)
and one-third from charitable bodies.27 We therefore
obtained data on UK government health research
funding for the ﬁve years from 2008 to 2012 from NIHR
(England), the Chief Scientist’s Ofﬁce (CSO, Scotland),
the National Institute for Social Care and Health
Research (NISCHR, Wales) and the Health and Social
Care Research Department (HSCRD, Northern
Ireland); and directly from the MRC. Charitable
research funding is provided by an extensive range of
organisations but 85% of funding is provided by ﬁve
charities: Arthritis Research Campaign (ARC), Cancer
Research UK (CRUK), Leukaemia and Lymphoma
Association, the Wellcome Trust and British Heart
Foundation (BHF).27 Since arthritis and rheumatism pri-
marily cause disability but not death we excluded the
ARC, but sought to obtain data on research funding
allocated between 2008 and 2012 from the other above
named charities. The Leukaemia and Lympohoma
Association declined to provide funding information so
their grants are not included in the analysis. Data were
obtained either from organisational websites if available
and otherwise by direct contact with the funding
organisation.
The 12 922 grants identiﬁed by the eight funders (the
Wellcome Trust, CRUK, BHF, MRC, NIHR, NISCHR,
CSO and HSCRD) were classiﬁed by the lead author
using grant titles and the UK Health Research
Classiﬁcation System (HRCS)28 with the exception of
MRC and NIHR who routinely classify their own grants
using the HRCS (3796 grants in total). Grants were allo-
cated to up to ﬁve of the following 21 health category
labels: blood, cancer, cardiovascular, congenital disor-
ders, ear, eye, infection, inﬂammatory and immune
system, injuries and accidents, mental health, metabolic
and endocrine, musculoskeletal, neurological, oral and
gastrointestinal, renal and urogenital, reproductive
health and childbirth, respiratory, skin, stroke, generic
health relevance, other. Categories of grants covering
more than one health area were equally apportioned
depending on the number of areas covered. For
example two allocated categories in one grant would be
equally apportioned 50%. Grants covering more than
ﬁve areas were categorised as generic health relevance.
Grants that did not ﬁt into any category were classiﬁed
as other, such as PhD posts that did not specify an area
of research.
Grant funding was adjusted to 2012 prices using the
UK HM Treasury Inﬂator Calculator29 and because
information regarding length of funding awards was not
consistently available, funding calculations were based
on the year of award. Total annual category-speciﬁc
funding was calculated by multiplying the category
apportioned percentage for each grant by the total
grant award and combining the resulting ﬁgures for
each category. Average annual funding per category was
then calculated.
Non-relevant grants were then excluded from the ﬁnal
analysis. These included grants awarded to overseas insti-
tutes, those solely for overseas research or those for the
arts, journalism, veterinarian or medical humanities
research. A full list of excluded grants is available on
request. To ensure that no relevant grants had been
excluded, a search was run on all excluded grant titles
for the words ‘tobacco’, ‘smoking’ or ‘nicotine’; none
were identiﬁed. Included grant titles (10 647 in total for
the 5-year study period) were further analysed for the 18
tobacco-related disease areas identiﬁed by WHO20 and
breast and prostate cancer for comparison purposes. As
before, equal percentages were applied where there
were two or more disease areas in any particular grant
title. An additional category of ‘tobacco’ was created to
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estimate direct investment in tobacco prevention
research and included all grants that contained
‘tobacco’, ‘smoking’ or ‘nicotine’ in their titles. All grant
titles identiﬁed in this manner were checked for rele-
vance to tobacco prevention. Total annual disease-
speciﬁc funding was calculated by multiplying the
disease-speciﬁc apportioned percentage for each grant
by the total grant award. Average annual funding per
disease area and for tobacco was then calculated.
Analysis
Descriptive analysis was carried out exploring all-cause
deaths, deaths attributable to tobacco and annual average
funding by health category, tobacco-related disease and
tobacco prevention research. Funding related to broad
HRCS categories included all research grant funding
(12 922 grants) in order to provide an overview of total
funding. Funding related to tobacco prevention and
disease research excluded non-relevant grants as per the
exclusion criteria (10 647 grants in total). We calculated
disease-speciﬁc annual average funding as a proportion
of total annual average funding and used linear regres-
sion analysis to assess the association between proportion
of funding and number of all-cause and tobacco-related
deaths. We further calculated the annual average
research spend per all-cause and tobacco attributable
death for each tobacco-related disease by dividing the
annual average funding for that disease by its annual
average number of all-cause and then, tobacco attribut-
able deaths. All analysis including regression analysis was
carried out using Microsoft Excel 2010.
RESULTS
Deaths from tobacco-related diseases
Across 2008–2012 an annual average of 110 500 deaths
were estimated to be attributable to tobacco, equating to
20% of all UK deaths per year. From the tobacco-related
diseases considered, ischaemic heart disease (IHD) was
responsible for the most deaths from all causes, but lung
cancer and chronic obstructive pulmonary disease
(COPD) contributed the most deaths from tobacco
(ﬁgure 1).
Research funding
Funding by health category
Total research funding for all health categories over the
5 years amounted to £6.69bn, equivalent to an annual
average of £1.34bn. Further information regarding spe-
ciﬁc funding by health category is available in online
supplementary ﬁgure S1.
Funding by tobacco prevention and tobacco-related disease
Following application of the exclusion criteria on non-
relevant grants, total research funding (of the remaining
10 647 grants) amounted to £6.05bn over the 5 years or
an annual average of £1.21bn. Total funding for diseases
identiﬁed as tobacco-related amounted to an annual
average of £130m or 10.8% of the total annual average
funding of £1.21bn (ﬁgure 2). Of all WHO
tobacco-related diseases, stroke received the largest
quantity of funding (£16.5m per year or 1.4% of total
annual average funding) followed by diabetes mellitus
(£11.7m, 1% of total) and colorectal cancer (£11m per
year). Research into stomach, liver and bladder cancer
each amounted to <£1m per year respectively or <0.1%
of total annual average funding. In particular, stomach
and liver cancer each received an average of <£400k in
research funding per year.
There were 78 grants including ‘smoking’, ‘tobacco’
or ‘nicotine’ in the grant title, of which two were related
to speciﬁc treatment for tobacco-related disease and so
were classiﬁed under their speciﬁc disease. The remain-
ing 76 all involved smoking prevention activities
Figure 1 Disease-specific
deaths: tobacco and all cause.
COPD, chronic obstructive
pulmonary disease; TB,
tuberculosis.
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including policy research or infrastructure support, and
were thus categorised as ‘tobacco prevention’.
An average of £5.1m was spent each year on tobacco
prevention research, or 0.42% of the total annual
average funding of £1.21bn.
Relation between research investment and mortality
We used all cause deaths by tobacco-related disease as a
measure of overall disease burden to analyse the relation
between disease burden and research investment. Linear
regression analysis demonstrated a weak and non-
signiﬁcant association (r2=0.16, p=0.1) between these vari-
ables. IHD had the highest number of deaths but the 5th
largest proportion of total annual average research
funding, equivalent to 0.64% of total funding,
(ﬁgure 3A); stroke received the most funding and had
the second highest number of deaths. Lung cancer and
COPD had the 3rd and 4th highest number of deaths
respectively but the 12th and 7th highest proportion of
funding (0.2% and 0.4% of total respectively). Stomach,
bladder and liver cancer had very low proportions of
overall funding (0.02%, 0.06% and 0.03% respectively)
and there was a noticeable difference in funding alloca-
tion between several diseases such as kidney cancer
(0.1%), diabetes mellitus (0.96%) and liver cancer
(0.03%) despite their similar annual average number of
deaths.
We carried out further analysis to explore the relation
between research investment and tobacco attributable
deaths (ﬁgure 3B). Linear regression analysis showed no
evidence of association (r2=0.01, p=0.74). Lung cancer
and COPD had the highest number of tobacco attribut-
able deaths but ranked 12th and 7th respectively in
funding allocation.
Stroke had the ﬁfth highest number of deaths but the
highest funding and many diseases with a similar
number of tobacco attributable deaths such as liver
cancer, stomach cancer or hypertensive diseases had
wide differences in funding allocation.
Research spending per all-cause and tobacco attributable death
TB, diabetes mellitus and cervical cancer received the
largest amount of funding per all-cause death at £26.8k,
£5k and £2.5k, respectively, (not shown in ﬁgure 4 due to
their relatively large size and effect on the overall scale of
the ﬁgure). Diseases with a higher number of deaths
such as IHD and lung cancer had a relatively small
amount of funding per death (£97 and £68, respectively).
However, the difference in number of deaths did not
account for all differences in funding. Kidney cancer,
stomach cancer and hypertensive diseases accounted for
similar numbers of deaths but were funded at £297, £43
and £804 per death, respectively, while prostate and oral
cancer, with a similar number of deaths were funded at
£450 and £278 per death, respectively, (ﬁgure 4).
TB, diabetes mellitus and cervical cancer received the
largest funding per tobacco-attributable death at
£141.2k, £29.3k and £16.3k, respectively, (ﬁgures not
included in ﬁgure 4) and in general those diseases with
fewer tobacco attributable deaths had higher spend per
attributable death. However, there was again wide vari-
ation in funding allocation particularly in diseases with
similar numbers of deaths: colorectal cancer received
£5k per tobacco attributable death, pancreatic cancer
£670 and bladder cancer £340 despite each having
around 2000 tobacco attributable deaths per year.
The two diseases with the highest number of tobacco
attributable deaths, lung cancer and COPD received £80
and £211 per attributable death (ﬁgure 4).
Research funding of tobacco prevention amounted to
just £46 per death from tobacco-related disease
(ﬁgure 4), equating to ∼£1 spent researching how to
prevent tobacco consumption for every £29 spent
researching the consequences of tobacco consumption.
Figure 2 Annual average
funding by tobacco-related
disease. (Funding awarded by the
Leukaemia and Lymphoma
Association is not included in this
analysis so funding for leukaemia
is likely to be higher than the
figure given). COPD, chronic
obstructive pulmonary disease;
IHD, ischaemic heart disease;
TB, tuberculosis.
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DISCUSSION
To the best of our knowledge this is the ﬁrst study to
investigate research investment in tobacco-related
disease and prevention in the UK. It found that 20% of
all deaths each year are from tobacco-related disease,
equating to 110 000 people. Over £1.2bn is invested in
health research by governmental and charitable bodies
each year, £130m of which is on tobacco-related disease
and £5m on tobacco prevention or 10.8% and 0.42% of
total annual funding respectively. Investment in research
into different tobacco-related diseases varies widely from
an annual average of £16m for stroke research to £216k
for stomach cancer. Investment bears little relation to
either overall mortality or tobacco attributable mortality:
IHD had the largest number of overall deaths but the
ﬁfth highest proportion of research funding, while lung
cancer had the highest number of tobacco attributable
deaths but the 13th largest proportion of funding.
In addition investment in tobacco prevention compared
to treatment for tobacco-related disease is relatively low:
£46 for every tobacco attributable death spent on
tobacco prevention and £29 spent on researching dis-
eases arising from tobacco use for every pound spent on
tobacco prevention. It thus appears that research invest-
ment into tobacco-related disease and prevention is not
associated with overall disease burden as measured by
mortality or by degree of disease risk as measured by
attributable mortality.
Figure 3 (A) Annual average all
cause deaths versus proportion of
funding received. (B) Annual
average tobacco attributable
deaths versus proportion of
funding received. COPD, chronic
obstructive pulmonary disease;
IHD, ischaemic heart disease;
TB, tuberculosis.
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There is a history of relatively low investment into both
COPD and lung cancer research.14 This has been attribu-
ted to both the general public and researcher ‘victim
blaming’, ‘victims’ being ill through their own decision to
smoke consequently making fund raising more difﬁcult
and researchers more reluctant to enter an ‘unpopular’
ﬁeld of research.30 31 Published research shows a higher
proportion of studies concerned with tobacco disease
treatment rather than addiction19 and although studies
into lung cancer are now published in journals of a higher
than average impact factor,14 general tobacco-related
studies in the past have been in lower impact journals.32 It
is not clear why certain diseases are relatively underfunded
and there are likely to be a variety of contributory factors
including perceptions associated with tobacco research,
availability of researchers and availability of appropriate
funding. Being able to highlight funding levels, as this
study has attempted to do, is thus an important step in
attempting to redress any imbalances identiﬁed. Mortality
is a straightforward, if not comprehensive, measure of
disease burden and although not necessarily representa-
tive of total disease burden (see below) could usefully be
used in any national or international research prioritisa-
tion exercise. Studies that have used this measure have
shown similar results: in the US a ninefold difference in
funding per death of lung cancer compared to breast
cancer33 and an estimated $1.2k spent on research per
death of lung cancer compared to $27k per death of
breast cancer,34 while in the UK research spending on
lung cancer accounted for just 1.4% of all cancer funding
compared to 22% of all deaths.14 The stark difference
between 5-year survival of, for example, breast and lung
cancer may not show the impact of research investment
difference but does highlight the importance of equity of
research investment in relation to need rather than
demand.
Alternate methods of measuring disease burden
include years of life lost (YLL), disability adjusted life
years (DALY), economic burden and prevalence. YLL
and DALYs take into account the age at which a person
dies and the time spent ill before dying and as such
provide a more in-depth measure of societal burden.35
We used mortality as a measure of burden of disease
because it is simple and unequivocal, but acknowledge
that this approach excludes the impact of time spent ill
before death or age of death. Comparisons between dif-
ferent measures of burden have shown similarity in
funding compared to burden in diseases at either end
of the funding spectrum but some differences for those
in the ‘middle ground’.36 37 Regardless of the metric
used, there is a consistency in certain diseases being
relatively well funded (breast and prostate cancer,
leukaemia) and others relatively poorly funded (lung,
bladder and stomach cancer, dementia).35–39 Despite its
relative simplicity, mortality may well then be a useful
starting point while acknowledging that combing this
with other measures such as DALYs might provide a
more complete picture of funding relative to population
disease burden. Using the SIR rather than smoking
prevalence estimates to calculate tobacco attributable
mortality can over estimate number of deaths,40 41
however it is the most commonly used and accepted
methodology42 and is particularly useful for those coun-
tries which do not have valid data on smoking preva-
lence. The use of tobacco attributable deaths allowed us
to assess the relation between level of risk and research
investment, and for these comparisons we used the same
funding information as for all deaths. Funding informa-
tion was gained from a broad range of public and charit-
able bodies that attempted to include all major sources
of research funding. However, it is likely that some
sources have been missed; in addition commercial and
Figure 4 Research spend per
death (all-cause and tobacco
attributable). COPD, chronic
obstructive pulmonary disease.
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industry funded research is not included in this study
given the difﬁculty in obtaining such data and its lack of
direct inﬂuence on public policy. Nevertheless such
funding may well have an inﬂuence on government or
charitable research investment not least by highlighting
areas of research that are not of a commercially high
enough interest to proﬁt making organisations and thus
requiring government input. In addition this study did
not look at international funding that may have an inﬂu-
ence on UK funding and as such does not provide a
wider picture of all potentially relevant tobacco-related
research investment. This study does nevertheless repre-
sent a sizeable portion of UK research funding collected
and collated in a comprehensive manner. Classiﬁcation
was carried out by the ﬁrst author alone, but was carried
out a number of times and used the HRCS to ensure
consistency. Classiﬁcation carried out by two organisa-
tions corresponded closely to similar classiﬁcations
carried out by the author. Research funding was allo-
cated to the year of grant award rather than divided
across years of award potentially leading to over or
under estimation of funding in some years. The primary
aim of our research was to compare funding with mor-
tality not to calculate annual trends or to reﬂect differ-
ing annual research priorities. Therefore, despite the
obvious skew in annual funding we felt that average
annual funding was the most appropriate method with
which to compare to average annual deaths.
The UK has the strongest range of tobacco control pol-
icies in Europe43 and historically has had a strong track
record of commitment to evidence-based smoking cessa-
tion services.44 Primary prevention in general tends to
provide excellent value for money45 and targeted preven-
tion such as brief interventions to middle-aged smokers
can save money.46 The continued reduction in smoking
prevalence is slowing such that there is now little differ-
ence in smoking rates between 2007 and 201247 and it is
often the more deprived and vulnerable groups that con-
tinue or start to smoke.48 49 It could be argued that
understanding why people smoke, why they start smoking
and helping them to stop would form the spearhead of
any research investment. Prevention is a fundamental
principle in the NHS 5-Year Forward plan50 emphasising
the importance of research into preventing smoking
uptake, reduction in smoking prevalence and identiﬁca-
tion of effective tobacco control policies.
There is substantial investment in health research in
the UK, yet this covers discrepancies in the amount
certain diseases are funded compared to other diseases
and to mortality burden. Research into prevention
appears to be particularly underfunded. A national
research strategy, coordination or system of prioritisation
would enable a more robust approach to research invest-
ment and create a more equitable investment in different
disease areas and of primary prevention and treatment.
We would argue that research allocation based on a rec-
ognisable and coordinated prioritisation system would
allow for substantial investment in areas with the greatest
burden. However, it is measured, tobacco use creates the
single highest health burden in the UK and investment
in research should reﬂect this burden.
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